P

Progyny

Fertility benefits management for employers

Executive Assistant

Full-TimeUpdated on 10/21/2026
$80k - $90k/yr+ Bonus + Company equity + 401(k) match
Senior
New York, NY, USA
HybridThree days a week in the office.
Administrative & Executive AssistanceExecutive Support
No H1B Sponsorship

About the job

Requirements
  • At least 5 years of administrative experience supporting multiple executives, including C-suite leaders.
  • Proficiency in Microsoft Outlook and demonstrated ability to maintain complex executive calendars; strong skills in Excel, Word, and PowerPoint.
  • Comfort using digital applications and online resources.
  • Ability to organize work, manage multiple priorities, and ensure tasks are completed.
  • Ability to anticipate needs weeks, months, and quarters in advance.
  • Ability to make accurate, timely administrative judgments, act independently when appropriate, and escalate when necessary.
  • Ability to collaborate effectively with people across functions, backgrounds, and organizational levels.
  • Candidates must be based in the United States and authorized to work in the United States without sponsorship, now or in the future.
Responsibilities
  • Manage complex calendars and schedule meetings for multiple executives, coordinating priorities, logistics, and follow-up needs.
  • Communicate regularly with executives by email, text/SMS, telephone, and face-to-face conversations to manage calendars, meetings, and evolving priorities.
  • Liaise between executives and internal departments, teams, and external stakeholders.
  • Coordinate domestic travel arrangements and prepare itineraries.
  • Prepare and submit monthly expense reports accurately and on time.
  • Order daily lunch for the executive team.
  • Assist executives with printing, scanning, mailing, and other ad hoc administrative needs.

About the company

Progyny is a fertility benefits manager that partners with employers to offer comprehensive fertility and family-building services to employees. It provides a wide range of services including IUI, IVF, fertility preservation, adoption assistance, and surrogacy support, all integrated into employers’ existing benefits packages. The company makes money by signing contracts with employers, typically using a fixed-fee or per-employee-per-month pricing model, and it works to deliver better clinical outcomes to reduce overall treatment costs. Unlike broader health insurers, Progyny focuses specifically on fertility care and family-building, emphasizing measurable clinical results and seamless workflow within the benefits ecosystem. Its goal is to expand access to inclusive fertility benefits while improving outcomes and controlling costs for employers and employees.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2008

Get referred to Progyny

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $350.5 million, with gross margin expanding to 25.5%.
  • Progyny repurchased 10.8 million shares since November 2025, supporting per-share economics.
  • Provider-search recognition for FertilityEquity strengthens network quality and member trust into 2027.

What critics are saying

  • Q2 2026 growth still lapped a $48.5 million transition client wind-down.
  • August 2026 guidance disappointed investors; shares fell after lower third-quarter expectations.
  • Carrot Fertility and Maven Clinic pressure pricing; employers can bundle fertility elsewhere by 2027.

What makes Progyny unique

  • Progyny owns employer fertility navigation, specialty networks, and care advocates.
  • FertilityEquity and provider search make culturally responsive care visible to members.
  • Progyny Select extends coverage to smaller employers through brokers for 2027 plan years.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Company Equity

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

1%
AD HOC NEWS
Oct 20th, 2026
JPMorgan cuts target for Sotera Health stock from USD 18 to USD 17.

JPMorgan cuts target for Sotera Health stock from USD 18 to USD 17. Published on 10/20/2026 at 18:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Second-quarter revenue reached USD 321.38 million on June 30, 2026. Sotera Health stock costs EUR 16.00 on October 20, 2026 at 6:48 p.m. CEST. Analyst target and reporting date. * JPMorgan cut its Sotera Health target from USD 18.00 to USD 17.00 on October 14, 2026. * Second-quarter revenue reached USD 321.38 million for the period ended June 30, 2026. * Sotera Health stock was at EUR 16.00 at Lang & Schwarz on October 20, 2026 at 6:48 p.m. CEST. * The company is scheduled to report third-quarter 2026 results on November 3, 2026. Sotera Health stock became the subject of a JPMorgan downgrade on October 14, 2026, when the bank moved its rating from Neutral to Underweight and cut its target from USD 18.00 to USD 17.00, as Markets Insider reported. At Lang & Schwarz, the stock was trading at EUR 16.00 on October 20, 2026 at 6:48 p.m. CEST. Discover more Hire M&A Advisors Invest in Stocks Revenue growth remains visible. The company reported second-quarter 2026 revenue of USD 321.38 million for the period ended June 30, 2026, up 9.20 percent from the prior-year quarter. Net income reached USD 53.64 million, or USD 0.19 per diluted share, compared with USD 8.00 million and USD 0.03 per diluted share in the second quarter of 2025, according to Sotera Health. Stock position and valuation. The Nasdaq quote stood at USD 17.98 on October 20, 2026 at 12:57 p.m. ET. Sotera Health had a market capitalization of USD 5.1 billion and a trailing price-to-earnings ratio of 31.43 at that timestamp. Its 52-week range was USD 13.09 to USD 19.85, placing the quote 9.42 percent below the high and 37.36 percent above the low. Trading volume reached 590,875 shares. Target and reporting date matter. JPMorgan's USD 17.00 target stood 5.45 percent below the Nasdaq price of USD 17.98 on October 20, 2026. The bank cited uncertainty around future volume growth and the medical device end market in its October 14 note, as Markets Insider reported. Sotera Health is scheduled to report third-quarter 2026 results on November 3, 2026, with consensus earnings per share of USD 0.24, according to MetaCap. Peer valuation stays mixed. Comparison with peers Progyny (Nasdaq, USD): down 2.17 percent, P/E 29.80, market capitalization USD 2.06 billion, according to MetaCap. DaVita (NYSE, USD): down 0.98 percent, P/E 15.80, market capitalization USD 11.95 billion, according to MetaCap. What the target signals. The lower JPMorgan target contrasts with Sotera Health's 9.20 percent second-quarter revenue growth and sets a clear test for the November results. Investors will have fresh operating figures to compare with the USD 17.00 target. On Nasdaq, the stock was trading at USD 17.98 on October 20, 2026 at 12:57 p.m. ET. The further course of trading is shown by the continuously updated real-time quote of Sotera Health stock. Sotera Health at a glance. * Company: Sotera Health Company * ISIN: US83601L1026 * Ticker: SHC * Primary exchange: Nasdaq * Price Lang & Schwarz as of October 20, 2026, 6:48 p.m. CEST: EUR 16.00 * Market capitalization: USD 5.1 billion as of October 20, 2026 * 52-week range: USD 13.09-19.85 as of October 20, 2026 * Sector / Industry: Health Care / Miscellaneous Health and Biotechnology Services * Next earnings date: November 3, 2026 Discover more Compare Lab Gear Track Biotech Read Company News Sponsored Ad Sotera Health Co stock: new analysis - 23 October. Fresh Sotera Health Co information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US83601L1026 | SHC | boerse | 70376329 | bgmi

Military Industry Today
Oct 15th, 2026
Progyny to present new menopause research at The Menopause Society 2026 Annual Meeting.

Progyny to present new menopause research at The Menopause Society 2026 Annual Meeting. NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that it will present new research evaluating real-world outcomes from its Menopause and Midlife program and exhibit at The Menopause Society 2026 Annual Meeting in San Diego, October 20 - 24, 2026. As a leading provider of employer-sponsored menopause care around the globe, Progyny is committed to expanding access to high quality, evidence-based care and demonstrating its impact on women's health outcomes. The research, "Scaling Access to Menopause Care: Real-World Symptom Improvement in an Employer-Sponsored Program," will be presented by Gloria Richard-Davis, MD, MBA, Regional Dean at Morehouse School of Medicine, member of Progyny's Medical Advisory Board, and former Secretary and two-term member of The Menopause Society's Board of Trustees. The study was conducted in partnership with Morehouse School of Medicine and evaluated access, engagement, and changes in menopause symptoms among women participating in Progyny's employer-sponsored Menopause and Midlife program. "Menopause is a significant health transition, yet too many women still struggle to find clinicians with the expertise to provide individualized, evidence-based care," said Janet Choi, MD, Chief Medical Officer, Progyny. "This research demonstrates the potential to translate menopause expertise into a model that can reach more women and meaningfully improve their symptoms. That's an important step toward making high-quality menopause care a more accessible part of women's healthcare." Progyny's participation in The Menopause Society Annual Meeting reflects the company's continued expansion of its clinical research and solutions across the entire women's health spectrum. Building on more than a decade of experience in fertility and family building, Progyny now supports members across the reproductive health continuum, including preconception, fertility, pregnancy, postpartum, and menopause and midlife. Dr. Richard-Davis will present the research during Concurrent Session #2 on Thursday, October 22, from 5:15-5:30 PM PT. The Progyny team will be at Booth #211 if there is interest to learn more about its Menopause and Midlife program and broader women's health offerings. To learn more about Progyny's Menopause and Midlife offering, please visit Progyny.com/menopausesupport About Progyny Progyny is a global leader in women's health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx(R), and personalized guidance from Progyny Care Advocates(R) to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com. For Further Information, Please Contact: Alexis Ford Investors: James Hart Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Military Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Progyny
Sep 4th, 2026
How culturally responsive care is helping reduce disparities in fertility treatment.

How culturally responsive care is helping reduce disparities in fertility treatment. Fertility care is deeply personal. Every patient brings unique experiences, values, and cultural perspectives to their care. Yet many patients from historically marginalized communities report feeling unwelcome or misunderstood in healthcare environments where their lived experiences were not reflected in the care they received. While many factors contribute to these experiences, one is the longstanding lack of diversity within the healthcare workforce. Although women make up about half of the U.S. population and Black Americans nearly 14%, physicians remain disproportionately white and male-only 39% of practicing physicians are female, and just about 5% are Black. For many people seeking fertility treatment, having the option to receive care from a provider who understands their background and respects their values, preferences and lived experiences can help foster trust, communication, and engagement during treatment. Choice in care matters. In response, Janet Choi, MD, Progyny Chief Medical Officer, and other network physicians collaborated with Morehouse School of Medicine, Ferring Pharmaceuticals, and EngagedMD to develop educational content focused on advancing culturally responsive fertility care. The FertilityEquity(TM) training program is comprised of 26 evidence-based learning modules combining educational content, practical guidance, and real patient stories illustrating care gaps. The curriculum explores disparities in fertility care and delivers actionable strategies to support more equitable patient experiences and outcomes. Providers and clinics completing the coursework are recognized in the Progyny Provider Search Tool, enabling members to identify practices that have demonstrated a commitment to culturally responsive care. "Members can now more easily identify providers who have invested in culturally responsive fertility care, which is essential to improving both trust and outcomes. For many patients-particularly women of color-experiences of feeling dismissed or not fully heard remain far too common, and that can delay engagement with care at critical moments," explains Dr. Choi. The need for this type of support is reflected in persistent disparities in fertility care. Research shows that while Black women experience infertility at disproportionately higher rates, they often seek fertility care later and face greater barriers to accessing treatment. Black women may spend more than 1.5 additional years trying to conceive before seeking fertility support and are significantly more likely to report difficulty finding a preferred provider. Additionally, Black and Hispanic women are up to six times more likely to have difficulty finding a physician with whom they feel comfortable. By helping members identify providers who have completed culturally responsive care training, Progyny aims to make it easier for individuals to find care that aligns with their needs and fosters trust throughout the fertility journey. "Age is a significant factor that influences the success of fertility interventions and pregnancy outcomes. It is critical that disparities-and resultant barriers-don't contribute to delays in seeking care, particularly for historically underserved populations," says Gloria Richard-Davis, MD, MBA, Regional Dean of the Morehouse School of Medicine and Progyny Medical Advisory Board member. "With the opportunity to identify aligned providers, members can seek fertility care earlier and with greater confidence." Strong provider-patient relationships are foundational to high-quality fertility care. When patients feel heard, respected, and understood, they are more likely to engage in their care, make informed decisions, and feel empowered throughout their fertility journey. The response to the coursework has been overwhelmingly positive; participants eager to pursue the recognized culturally competent care designation to better meet the needs of diverse patient populations. Progyny's partnership with Morehouse, Ferring, and EngagedMD reflects a broader effort to raise the standard of care-ensuring that more individuals can access providers who understand their needs, engage earlier in treatment, and ultimately achieve better outcomes. This is an important step toward a future where every patient feels seen, heard, and supported throughout their fertility journey. If you're curious to learn more or if you're a provider looking to take the course, please visit FertilityEquity.

Yahoo Finance
Aug 12th, 2026
2 cash-heavy stocks to watch and 1 to avoid

Two healthcare companies with strong cash positions are attracting investor attention, whilst a fertility benefits provider faces challenges. Progyny holds $214.4 million in net cash, representing 14.2% of its market capitalisation. However, the company has struggled with underwhelming unit sales over the past two years and demonstrates below-average returns on capital. Trading at $27.95 per share, Progyny commands a 13.9x forward price-to-earnings ratio. Molina Healthcare maintains a net cash position of $1.22 billion, or 11.9% of market cap. The managed healthcare provider has achieved 13.7% annual revenue growth over five years, outpacing sector averages. Operating across 21 states, Molina serves low-income individuals through Medicaid, Medicare, and Marketplace programmes. Axos Financial, a digital banking and financial services company, holds $39.48 million in net cash, though this represents just 0.7% of its market capitalisation.

Market Wire News
Aug 7th, 2026
Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference.

Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference. August 07, 2026 10:51:30 am NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny's investor relations website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. Market Wire News envision a world where everyone can realize their dreams of family and ideal health. Its outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Its benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: Investors: James Hart [email protected] Media: Alexis Ford [email protected]